TABLE 2.
Antimicrobial MICs for Acinetobacter species recipients and transconjugants
| Strain | MIC (mg/liter)a |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATMb | CAZb | IPM | MEM | TZP | AMK | GEN | TOB | CIP | CST | FOF | SXT | TGCb | |
| CHI-40-1 | 48 (R) | ≥256 (R) | ≥32 (R) | ≥32 (R) | 96 (R) | 48 (R) | ≥256 (R) | 12 (R) | ≥32 (R) | 0.75 (S) | 8 | ≥32 (R) | 0.75 (R) |
| 69122-EW | 3 (S) | ≥256 (R) | ≥32 (R) | ≥32 (R) | 24 (R) | 32 (R) | 2 (S) | 8 (R) | ≥32 (R) | 0.75 (S) | 32 | 0.25 (S) | 1 (R) |
| 73668-ECT | 16 (R) | ≥256 (R) | ≥32 (R) | ≥32 (R) | 48 | 6 (S) | 192 (R) | ND | ≥32 (R) | 0.5 (S) | 4 | 0.25 (S) | 0.5 (I) |
| 74312-EC | 48 (R) | ≥256 (R) | ≥32 (R) | ≥32 (R) | ≥256 (R) | 48 (R) | 96 (R) | 12 (R) | ≥32 (R) | 0.5 (S) | 16 | ≥32 (R) | 0.75 (R) |
| AG3528 | 16 (R) | 3 (S) | 0.75 (S) | 0.75 (S) | 2 | 2 (S) | 0.75 (S) | 0.75 (S) | 4 (R) | 1 (S) | 16 | 0.125 (S) | ND |
| UAB190 | 0.125 (S) | 0.25 (S) | 0.38 (S) | 0.047 (S) | 2 | 2 (S) | 8 (R) | 1.5 (S) | 0.006 (S) | 0.5 (S) | 3 | 0.094 (S) | ND |
| AG3528NDMP1 | 16 (R) | ≥256 (R) | ≥32 (R) | ≥32 (R) | 96 | 3 (S) | 0.75 (S) | 0.75 (S) | 3 (R) | 1 (S) | 16 | 0.125 (S) | ND |
| UAB190NDMP2 | 0.064 (S) | ≥256 (R) | 24 (R) | 4 (I) | 256 | 2 (S) | 8 (R) | 1.5 (S) | 0.006 (S) | 0.5 (S) | 3 | 0.094 (S) | ND |
a
Antimicrobial susceptibility results based on EUCAST pharmacokinetic/pharmacodynamic (PK/PD) non-species-specific breakpoints. R, resistant; I, intermediate resistance profile; S, sensitive; ATM, aztreonam; CAZ, ceftazidime; IPM, imipenem; MEM, meropenem; TZP, piperacillin-tazobactam; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; CST, colistin sulfate; FOF, fosfomycin; RIF, rifampin; SXT, co-trimoxazole; TGC, tigecycline; ND, not determined.
b
Species-specific Acinetobacter species breakpoints not available.